Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Abstract

TPS2079 Background: GBM, the most common primary brain tumor in adults, has an aggressive clinical course and a median survival of 15–18 months in clinical trial populations. Approximately 40% of pts with GBM have tumors with an MGMT-methylated promoter, which is associated with sensitivity to TMZ. New treatment options for pts with GBM are desirable, particularly for those with MGMT-unmethylated GBM, as TMZ efficacy is historically marginal in this population. Nivolumab, a fully human IgG4 monoclonal antibody to the programmed death-1 receptor, has shown clinical activity and increased survival in pts with metastatic melanoma, non–small-cell lung cancer, and renal cell carcinoma. CheckMate-498 (NCT02617589) is a phase 3 study designed to compare overall survival (OS) of nivolumab or TMZ, each in combination with RT, in pts with newly diagnosed MGMT-unmethylated GBM. In a companion phase 2 trial (CheckMate-548; NCT02667587), eligible pts with MGMT-methylated tumors (N = 320) will be randomized to RT + TMZ + nivolumab vs RT + TMZ + placebo, with OS as the primary objective. Methods: Eligibility criteria include newly diagnosed, histologically confirmed, MGMT-unmethylated (centrally confirmed) GBM in pts aged ≥ 18 years with Karnofsky performance status ≥ 70. Pts with prior treatment for GBM and recurrent or secondary GBM are ineligible. Approximately 550 pts will be randomized to receive nivolumab + RT followed by nivolumab, or TMZ + RT followed by TMZ. Treatment will continue until progression or unacceptable toxicity. The primary objective is to compare OS with nivolumab + RT vs TMZ + RT; secondary objectives include progression-free survival and 2-year survival rate. Exploratory objectives include safety, biomarker analyses, and neurocognitive outcomes. Patients will be followed for safety and tolerability, tumor progression, and survival. At least 397 events, with an interim analysis after ≥ 298 events, will provide 90% power to detect a hazard ratio of < 0.72. Clinical trial information: NCT02617589.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.tps2079

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 53

Metadata

Authors
Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., Strauss, L. C., Latek, R. R., Paliwal, P., Weller, M., & Reardon, D. A.
Affiliations
  • Duke Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Medical University of Vienna (AT)
  • Johns Hopkins University (US)
  • University of California, San Francisco (US)
  • University of California, Los Angeles (US)
  • Bristol-Myers Squibb (United States) (US)
  • University Hospital Zurich (CH)
  • Harvard University (US)
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
TPS2079-TPS2079
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2508076331
Cited by
53
References
0
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 18 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 1
Type
conference abstract
Language
en
Open access
closed
Locations
Journal of Clinical Oncology (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
glioblastoma, MGMT unmethylated, nivolumab, temozolomide, radiotherapy, immune checkpoint inhibitors, PD-1 inhibitors, overall survival, newly diagnosed glioblastoma, combination therapy, immunotherapy versus chemotherapy, MGMT promoter methylation, progression-free survival, neuropsychological outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.tps2079
The paper
Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., Strauss, L. C., Latek, R. R., Paliwal, P., Weller, M., & Reardon, D. A. (2016). A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.tps2079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.